leadf
logo-loader
viewBiocept Inc

Biocept pursuing new strategy with a physician association using its liquid biopsy cancer tests

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive the liquid biopsy test provider has struck up an agreement with an undisclosed independent physician association in California to provide liquid biopsy testing services to its physicians and patients. Nall says this is the first value-based delivery system partnership of its kind for Biocept. Nall also mentioned the company will soon be launching its cerebral spinal fluid liquid biopsy test.

Quick facts: Biocept Inc

Price: 5.12 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $68.59 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Biocept announces Highmark has made a positive coverage determination on...

Biocept (Nasdaq: BIOC) CEO Michael Nall joined Steve Darling from Proactive with news the company has received positive news from Highmark, America’s fourth-largest Blue Cross Shield affiliate. That news being Biocept's Target Selector liquid biopsy assays have been accepted for medical coverage...

on 23/9/20

2 min read